{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T21:30:43Z","timestamp":1772659843179,"version":"3.50.1"},"reference-count":109,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["GPC2020\/GI1597"],"award-info":[{"award-number":["GPC2020\/GI1597"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.02311.CEECIND\/CP1596\/CT0004"],"award-info":[{"award-number":["2020.02311.CEECIND\/CP1596\/CT0004"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022.01175.PTDC"],"award-info":[{"award-number":["2022.01175.PTDC"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["DL57\/2016\/CP1334\/CT0006"],"award-info":[{"award-number":["DL57\/2016\/CP1334\/CT0006"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/147463\/2019"],"award-info":[{"award-number":["SFRH\/BD\/147463\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/110001\/2015"],"award-info":[{"award-number":["SFRH\/BPD\/110001\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50006\/2020"],"award-info":[{"award-number":["UIDB\/50006\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACS Chem. Neurosci."],"published-print":{"date-parts":[[2023,2,15]]},"DOI":"10.1021\/acschemneuro.2c00675","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T18:47:04Z","timestamp":1675450024000},"page":"554-572","source":"Crossref","is-referenced-by-count":14,"title":["Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences"],"prefix":"10.1021","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-0696","authenticated-orcid":true,"given":"Sara C.","family":"Silva-Reis","sequence":"first","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"},{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-6197","authenticated-orcid":true,"given":"Ivo E.","family":"Sampaio-Dias","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"given":"Vera M.","family":"Costa","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Xavier Cruz","family":"Correia","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"given":"Hugo F.","family":"Costa-Almeida","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"given":"Xerardo","family":"Garc\u00eda-Mera","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, E-15782 Santiago de Compostela, Spain"}]},{"given":"Jos\u00e9 E.","family":"Rodr\u00edguez-Borges","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]}],"member":"316","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00256.x"},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1010514"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.2174\/1574889811308020004"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.2174\/138955712798868995"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2003.08.002"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2012.05.029"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1460141"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.05980.x"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2004.11.001"},{"key":"ref10\/cit10","unstructured":"Guan, J.; Thomas, G. B.; Batchelor, D. C.; Gluckman, P. D. Neuroprotective effects of gly-pro-glu following intravenous infusion. PCT Int. Appl. WO 2005042000 A1 20050512, 2005."},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2003.08.032"},{"key":"ref12\/cit12","unstructured":"Batchelor, D. C.; Thomas, G. B.; Breier, B. H. H. Antibodies to glycine-proline-glutamate tripeptide. U.S. Pat. Appl. Publ. US 20060035279 A1 20060216, 2006."},{"key":"ref13\/cit13","unstructured":"Thomas, G. B.; Breier, B. H. H.; Batchelor, D. C. Anti-GPE antibodies, their uses, and analytical methods for GPE (tripeptide glycyl-L-prolyl-L-glutamic acid). PCT Int. Appl. WO 2002074245 A2 20020926.2002."},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.07.002"},{"issue":"1","key":"ref15\/cit15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1051\/ject\/200941037","volume":"41","author":"Mitchell S. J.","year":"2009","journal-title":"J. ExtraCorporeal Technol."},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0435"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(89)80032-4"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00473-4"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1039\/c1py00028d"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1999.7168"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00290.2014"},{"key":"ref22\/cit22","unstructured":"Krissansen, G. W.; Kanwar, J. R. Treatment of demyelinating diseases. PCT Int. Appl. WO 2002030447 A2 20020418, 2002."},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199901180-00031"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.04.033"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200408260-00029"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061280"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-019-00130-x"},{"issue":"9","key":"ref28\/cit28","first-page":"1111","volume":"4","author":"Nilsson-H\u00e5kansson L.","year":"1993","journal-title":"NeuroReport"},{"key":"ref29\/cit29","unstructured":"Gluckman, P. D.; Christopher, E.; Guan, J. Protection of dopaminergic neurons from Parkinson\u2019s disease with neuroprotective tripeptide. U.S. Patent 7,485,630 B2, 2001; U.S. Patent 6187906 B1 20010213, 2001."},{"key":"ref30\/cit30","unstructured":"Gluckman, P. D.; Christopher, E.; Guan, J.; Krishnamurthi, R. V. M. Methods to improve neuronal outcome. U.S. Pat. Appl. Publ. US 20020035066 A1 20020321, 2002."},{"key":"ref31\/cit31","unstructured":"Tajrena, A. Tripeptide GPE and analogs for regulation of weight. PCT Int. Appl. WO 2002076208 A1 20021003, 2002."},{"key":"ref32\/cit32","unstructured":"Gluckman, P. D.; Sirimanne, E. S.; Krissansen, G. W.; Kanwar, J. R. Composition and methods using tripeptide GPE and related compounds to improve neural outcome. U.S. Pat. Appl. Publ. US 20030027760 A1 20030206, 2003."},{"key":"ref33\/cit33","unstructured":"Gluckman, P. D. Composition and methods using tripeptide GPE and analogs thereof for immunomodulation. PCT Int. Appl. WO 2003086323 A2 20031023, 2003."},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)01988-0"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnr.0000127461.15985.07"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00338-8"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.2174\/157488908784534630"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.03.003"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812394106"},{"key":"ref41\/cit41","unstructured":"Sur, M.; Tropea, D.; Giacometti, E.; Jaenisch, R.; Wilson, N. R. IGF-1 and analogs for the treatment of Rett Syndrome and synaptic disorders. PCT Int. Appl. WO 2008153929 A1 20081218, 2008."},{"key":"ref42\/cit42","unstructured":"Muotri, A. R.; Carromeu, C.; Acab, A. Drug screening platform for rett syndrome. U.S. Pat. Appl. Publ. US 20150119327 A1 20150430, 2015."},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2017.09.001"},{"key":"ref44\/cit44","unstructured":"Neuren Pharmacheuticals Limited. Neuren Announces Glypromate Trial Preliminary Results. December 24, 2008. https:\/\/www.neurenpharma.com\/pdf\/8d1858c5-3377-409f-9cb4-1b1b72a314b9\/Neuren-Announces-Glypromate-Trial-Preliminary-Results.pdf (accessed January 9, 2023)."},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.11.040"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1039\/C7OB01544E"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1039\/B918763B"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1039\/D0GC00143K"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.10.005"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.10.004"},{"key":"ref51\/cit51","unstructured":"Gluckman, P.; Alexi, T. GPE analogs. U.S. Patent 7,112,570 B2, 2006."},{"key":"ref52\/cit52","unstructured":"Gluckman, P.; Alexi, T. GPE analogs. PCT Int. Appl. WO 2002016408 A2 20020228, 2002."},{"key":"ref53\/cit53","unstructured":"Abood, N. A.; Brimble, A. GPE analogs and peptidomimentics. PCT Int. Appl. WO 2002094856 A2 20021128, 2002."},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2005.08.026"},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.12.003"},{"key":"ref56\/cit56","unstructured":"Gluckman, P.; Thomas, G.; Guan, J.; Dragunow, M.; Anand, A.; de Rosbo, N.; Sieg, F.; Brimble, M. Effects of glycyl-2 methylprolylglutamate on neurodegeneration. U.S. Patent 7,605,177 B2, 2009."},{"key":"ref57\/cit57","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-013-8236-z"},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.6b00704"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.2174\/1570179414666170821115323"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00339"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.03.015"},{"key":"ref62\/cit62","unstructured":"Brimble, M. A.; Harris, P. W. R.; Sieg, F. Analogs of Glycyl-prolyl-glutamate. U.S. Patent 7,863,304 B2, 2011."},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2013.03.051"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2010.06.053"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1021\/jo9621581"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.08.001"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1021\/jm000007r"},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.10.006"},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00314-5"},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1088128"},{"key":"ref71\/cit71","doi-asserted-by":"publisher","DOI":"10.1021\/jm011091t"},{"key":"ref72\/cit72","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(01)90214-5"},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1039\/C4SC03089C"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1039\/D1MD00083G"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.1021\/ol034370e"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1039\/b605293b"},{"key":"ref77\/cit77","unstructured":"Harris, P. W. R; Brimble, M. A. Neuroprotective macrocyclic compounds and methods for their use. U.S. Patent 7,485,630 B2, 2009."},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.11.057"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.3390\/biom11010126"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200320"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-011-1210-x"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1378539"},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.1071\/CH12347"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.08.021"},{"key":"ref85\/cit85","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.07.001"},{"key":"ref86\/cit86","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S91864"},{"key":"ref87\/cit87","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201001068"},{"key":"ref88\/cit88","doi-asserted-by":"publisher","DOI":"10.1021\/nn402043c"},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-008-8021-8"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1985.tb03791.x"},{"key":"ref91\/cit91","doi-asserted-by":"publisher","DOI":"10.1101\/lm.51202"},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1039\/D0NJ04851H"},{"key":"ref93\/cit93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.07.002"},{"key":"ref94\/cit94","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007316"},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106704"},{"key":"ref96\/cit96","unstructured":"Acadia Pharmacheuticals Inc. Acadia Pharmaceuticals Submits New Drug Application in the U.S. FDA for Trofinetide for the Treament of Rett Syndrome. July 18, 2022. https:\/\/ir.acadia.com\/news-releases\/news-release-details\/acadia-pharmaceuticals-submits-new-drug-application-us-fda (accessed January 9, 2023)."},{"key":"ref97\/cit97","unstructured":"Neuren Pharmacheuticals Limited. Rett Syndrome New Drug Apllication acepepted for Priority Review by FDA. September 13, 2022. https:\/\/www.neurenpharma.com\/pdf\/5018fa4f-edf0-48fe-b5d8-048633d60706\/Rett-Syndrome-NDA-accepted-for-Priority-Review-by-FDA.pdf (accessed January 9, 2023)."},{"key":"ref98\/cit98","unstructured":"Neuren Pharmacheuticals Limited. Fragile X Syndrome. https:\/\/www.neurenpharma.com\/products\/trofinetide\/fragile-x-syndrome (accessed January 9, 2023)."},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.04.019"},{"key":"ref100\/cit100","unstructured":"Glass, L.; Bickerdike, M. J.; Snape, M. F. Treatment of autism spectrum disorders using glycyl-L-2-methylprolyl-L-glutamic acid. PCT Int. Appl. WO 2012102832 A1 20120802, 2012."},{"key":"ref101\/cit101","unstructured":"Glass, L.; Bickerdike, M. J.; Snape, M. F.; De Cogram, P. P. Treatment of autism spectrum disorders using glycyl-L-2-methylprolyl-L-glutamic acid. PCT Int. Appl. WO 2014085480 A1 20140605, 2014."},{"key":"ref102\/cit102","unstructured":"Glass, L.; Bickerdike, M. J.; Snape, M. F. Treatment of autism spectrum disorders using glycyl-L-2-methylproline-L-glutamic acid. U.S. Pat. Appl. Publ. US 20140147491 A1 20140529, 2014."},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2008.0629"},{"key":"ref104\/cit104","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-6-19"},{"key":"ref105\/cit105","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000149624.87661.18"},{"key":"ref106\/cit106","unstructured":"Grotta, J.; Gluckman, P. D. Tripeptide GPE, GPE analog G-2MePE, caffeine, and alkanol for treatment of central nervous system injury. PCT Int. Appl. WO 2005097161 A2 20051020, 2005."},{"key":"ref107\/cit107","doi-asserted-by":"publisher","DOI":"10.1159\/000105480"},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.109"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.12.003"}],"container-title":["ACS Chemical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acschemneuro.2c00675","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acschemneuro.2c00675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T05:54:25Z","timestamp":1701842065000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acschemneuro.2c00675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,15]]}},"alternative-id":["10.1021\/acschemneuro.2c00675"],"URL":"https:\/\/doi.org\/10.1021\/acschemneuro.2c00675","relation":{},"ISSN":["1948-7193","1948-7193"],"issn-type":[{"value":"1948-7193","type":"print"},{"value":"1948-7193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}